Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm familiar with the terms of the split.
Just wondering if the split shares are tradeable yet? And if so when were they unlocked?
Quick question. Has the pre-split shares been converted yet and if so, when were they? Thx
27 patents I found for RSCF. Why would someone spend this much $ if this was a pump and dump. Patents are at least 10k a piece. This company is gold with all these and a low float I think the share price might have been a little ahead of the actual news on the rapid climb, but this is a great long hold. I just wish the share price would reflect what I see. Perfect candidate for ows or for a buyout.
https://patents.justia.com/assignee/reflect-scientific-inc
At the current rate of 2/day, could be by next fri.
Then you haven't been paying attention. Post 18822.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158121465
You are right. I should have said the enrollment being finished, which everyone has said must be done before we get EUA. Obviously the results won't be out until the end of the yr.
Stock, go hit the pipe again. We already knew about the warrants. We are now just a week or so away from the trial being finished, with 0 adverse effects.
Yes! Hope the swiss keep it climbing steady. Would love to wakeup to that in the morning.
Even more $$$
New reuters article with quote from Javitt about delay.
“A couple of weeks after the end of the fourth quarter is what we’re expecting right now,” Jonathan Javitt, founder and chief executive of NeuroRx, said, telling Reuters that the new deadline reflects challenges in running a trial in the midst of a pandemic, including keeping staff safe.
https://www.reuters.com/article/health-coronavirus-relief-hldg/update-1-relief-pushes-back-data-release-date-for-covid-19-study-to-january-idUSL8N2HR1GQ
If that's your take, you have no clue. This means we will definitely get approval. Either EUA of Full after completion.
Trial continues
https://relieftherapeutics.com/newsblog/120-relief-therapeutics-and-neurorx-announce-continuation-of-rlf-100-trial-for-treatment-of-covid-19-respiratory-failure-trial-is-on-track-to-complete-enrollment-in-2020
ARCHIVE
RELIEF THERAPEUTICS AND NEURORX ANNOUNCE CONTINUATION OF RLF-100™ TRIAL FOR TREATMENT OF COVID-19 RESPIRATORY FAILURE: TRIAL IS ON TRACK TO COMPLETE ENROLLMENT IN 2020
05 November 2020
Geneva, Switzerland, and Radnor, PA, November 05, 2020 – RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company") and NeuroRx, Inc., announced that the independent Data Monitoring Committee (DMC) met yesterday and voted unanimously that NCT 04311697 should continue as planned to its full enrollment of 165 patients. Specifically, the committee identified no safety concerns and viewed the study as capable of reaching its prespecified endpoint (i.e. no finding of futility) in potentially proving that RLF-100™ (aviptadil) is superior to placebo in achieving recovery from respiratory failure in patients with critical COVID-19 at a statistically significant level.
RLF-100™ was granted FDA Fast Track Designation in June 2020 and was previously granted Orphan Drug Designation for the treatment of Acute Respiratory Distress Syndrome. In an earlier, open label study of patients with severe comorbidities that disqualified them from the randomized prospective trial, a statistically-significant (P<.0001) benefit in both recovery from respiratory failure and in survival was seen compared to control patients who received standard of care treatment (http://dx.doi.org/10.2139/ssrn.3665228).
The review by the DMC was based on data from 102 patients who were randomly assigned to intravenous RLF-100™ vs. placebo and who have completed 28 days or more of observation. All patients were hospitalized in intensive care units with respiratory failure treated by mechanical ventilation, non-invasive ventilation, or high-flow nasal oxygen. So far, 133 patients have been treated in this protocol. At current rates of enrollment (which may change as infection rates change) the study is expected to complete enrollment by mid-December and yield top-line data in January 2021.
Although the study remains blinded, the randomized data overall show that there have been no drug-related serious adverse events to date. Similarly, no drug-related adverse events were seen either in the open label study of the ongoing Expanded Access Protocol.
In contrast to other recently-reported trials, the RLF-100™ phase 2b/3 trial focuses on patients with critical COVID-19 who already require intensive care for respiratory failure. Currently there is no approved drug that has shown efficacy in this population, nor are there late-stage trials of other experimental therapeutics focusing on these patients.
The seven-person DMC included two independent biostatisticians, an epidemiologist/clinical trials expert, a bioethicist, a public representative and clinical experts in pulmonary and critical care medicine.
ABOUT VIP IN LUNG INJURY
Vasoactive Intestinal Polypeptide (VIP) was first discovered by the late Dr. Sami Said in 1970. Although first identified in the intestinal tract, VIP is now known to be produced throughout the body and to be primarily concentrated in the lungs. VIP has been shown in more than 100 peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation. Most importantly, 70% of the VIP in the body is bound to a rare cell in the lung, the alveolar type 2 cell, that is critical to transmission of oxygen to the body. VIP has a 20-year history of safe use in humans in multiple human trials for sarcoidosis, pulmonary fibrosis, asthma/allergy, and pulmonary hypertension.
COVID-19-related death is primarily caused by respiratory failure. Before this acute phase, however, there is evidence of early viral infection of the alveolar type 2 cells. These cells are known to have angiotensin converting enzyme 2 (ACE2) receptors at high levels, which serve as the route of entry for the SARS-CoV-2 into the cells. Coronaviruses are shown to replicate in alveolar type 2 cells but not in the more numerous type 1 cells. These same type 2 alveolar cells have high concentrations of VIP receptors on their cell surfaces giving rise to the hypothesis that VIP could specifically protect these cells from injury.
Injury to the type 2 alveolar cells is an increasingly plausible mechanism of COVID-19 disease progression (Mason 2020). These specialized cells replenish the more common type 1 cells that line the lungs. More importantly, type 2 cells manufacture surfactant that coats the lung and are essential for oxygen exchange. Other than RLF-100™, no currently proposed treatments for COVID-19 specifically target these vulnerable type 2 cells.
ABOUT RLF-100™
RLF-100™ (Aviptadil) is a formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Prof. Sami Said’s original work at Stony Brook University, for which Stony Brook was awarded an FDA Orphan Drug Designation in 2001. VIP is known to be highly concentrated in the lungs, where it inhibits coronavirus replication, blocks the formation of inflammatory cytokines, prevents cell death, and upregulates the production of surfactant. FDA has now granted IND authorization for intravenous and inhaled delivery of RLF-100™ for the treatment of COVID-19 and awarded Fast Track designation. RLF-100™ is being investigated in two placebo-controlled US Phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Since July 2020, more than 150 patients with Critical COVID-19 and Respiratory Failure have been treated with RLF-100™ under FDA-approved protocols. Information on the RLF-100™ Expanded Access program is at https://www.neurorxpharma.com/our-services/rlf-100.
ABOUT RELIEF THERAPEUTICS HOLDING AG
Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Relief holds orphan drug designations from the U.S. FDA and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief also holds a patent issued in the U.S. and multiple other countries covering potential formulations of RLF-100™.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on the OTCQB under the symbol RLFTF.
ABOUT NEURORX INC.
NeuroRx draws upon more than 100 years of collective drug development experience and is led by former senior executives of Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, PPD. In addition to its work on RLF-100™, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials. Its executive team is led by Prof. Jonathan C. Javitt, MD, MPH, who has served as a health advisor to four Presidential administrations and worked on paradigm-changing drug development projects for Merck, Allergan, Pharmacia, Pfizer, Novartis, and Mannkind, together with Robert Besthof, MIM, who served as the Global Vice President (Commercial) for Pfizer’s Neuroscience and Pain Division. Its Board of Directors and Advisors includes Hon. Sherry Glied, former Assistant Secretary, U.S. Dept. of Health and Human Services; Mr. Chaim Hurvitz, former President of the Teva International Group, Lt. Gen. HR McMaster, the 23rd National Security Advisor, Wayne Pines, former Associate Commissioner of the U.S. Food and Drug Administration, Judge Abraham Sofaer, and Daniel Troy, former Chief Counsel, U.S. Food and Drug Administration.
Contact:
RELIEF THERAPEUTICS Holding AG
Raghuram (Ram) Selvaraju, Ph.D., MBA
Chairman of the Board
contact@relieftherapeutics.com
NeuroRx, Inc.
Jonathan C. Javitt, M.D., MPH
Chairman and Chief Executive Officer of NeuroRx, Inc.
ceo@neurorxpharma.com
For media inquiries contact:
Relief (Europe)
MC Services AG
Anne Hennecke / Brittney Sojeva
Tel.: +49 (0) 211-529-252-14
Mail: relief@mc-services.eu
NeuroRx (United States)
David Schull
Russo Partners, LLC
david.schull@russopartnersllc.com
858-717-2310
Investor relations contact:
Relief (Europe)
Anne Hennecke / Brittney Sojeva
MC Services AG
relief@mc-services.eu
+49 (0) 211-529-252-14
NeuroRx (United States)
Brian Korb
Solebury Trout
bkorb@troutgroup.com
917-653-5122
"This gives us substantial confidence in the outcome of our ongoing Phase 2b/3 trial with the IV formulation of the drug."
From @austinroan on discord.
Thank you for your email.
We understand that it is difficult to sort through the various news sources to find the truth. As we have reported, our Phase 2b/3 trial passed the first interim analysis (which included an unblinded futility assessment) with positive results and a second interim analysis is slated to occur imminently, involving roughly two-thirds of the target number of patients to be enrolled (i.e., 102 out of a total 165 subjects). Furthermore, we have released data with our partner NeuroRx Inc. from the Expanded Access Program (EAP) with RLF-100 showing very intriguing clinical efficacy data in extremely critically ill COVID-19 patients (i.e., those with no other treatment options, who have been on ventilators or ECMO for extended periods of time) in whom none of the existing approved or experimental drugs have been shown to work at all. This gives us substantial confidence in the outcome of our ongoing Phase 2b/3 trial with the IV formulation of the drug.
As soon as we have new information from the trial, we will share it with the market and all stakeholders promptly.
We wish you and your loved ones continued health.
Kind regards,
Brittney Sojev
Credit Suisse does have 16.7m shares.
Maybe Francisco is seeing Credit Suisse already has 16.7m shares on file and is misinterpreting the data? When was this purchase made?
https://m.marketscreener.com/quote/stock/RELIEF-THERAPEUTICS-HOLDI-5527488/company/
I have been married 20 yrs, and love my wife, but yet, never truly knew what commitment was until this morning. I woke up, saw the swiss chart and felt nothing. Nada, nein, zip. 100% in on this and felt nothing seeing this dip. Either I am emotionally dead, or I am 10,000% committed. After seeing the swiss chart, I just started catching up on my posts. I just "know", we are all going to be fine. I have never had peace before about a stock.
Unfortunately, there are things your partner can do to make you stop loving them, and surely this stock has the same power, but absent of real info, it's not going to happen with me.
Long and strong! I'm in it til the end.
Hahahaha
That's a great idea!
Agreed!
On Y@hoo, they're actually talking about a stockholders party in Vegas after this pops. Only a 2 hr flt from Houston, so I'm in. Lord knows we all need it.
Thank you, but the DD I see on this board from you, and others like J-Belfort (thx for the PM btw, but I can't respond) aGuyUS and lots and lots of others, makes mine seem insignificant. I can't wait til you guys are rewarded, for all of your hard work inspiring others, like me. You guys deserve it.
Reading this board brought me in on my first buy of 26000 RLFTF on 8/4 for .18. Funny how at the time I was worried about overpaying. Lol. Good times.
Good eye? With Bausch? Hahahaha. Maybe I'm delirious from lack of sleep watching 2 markets and always waiting for those PR's, but that is funny!
Assuming Javitt's comment about merging with a NYSE company means a current NYSE company and not a future one, (ie: Relief), I think I've found a likely candidate after crawling down rabbit hole after rabbit hole for days. Admittedly only looking at current NYSE companies that are connected to Javitt or more importantly GEM.
Bausch Health (BHC) is a current NYSE company, and is listed in Gem's current portfolio under their previous name ICN Pharmaceuticals Inc. Well, they were ICN, then changed their name to Valeant, then Bausch Health. What caught my eye was a couple of things that may/may not be material:
1. Bausch's former name (ICN) is currently listed in Gem's portfolio.
2. Bausch is a huge global Pharma co. that likes to acquire other up and coming small cap pharmas. That's actually how they got their name after Valeant acquired Bausch and Lomb for 8.7b and thought the Bausch name garnered more respect after having a little bit of controversy selling their drugs for too much.
3. Bausch is obviously a big ophthalmology oriented company (Javitt's profession), but has tons and tons of drugs in it's pipeline (I stopped counting at 20)
4. With Javitt's work in Ophthalmology, he undoubtedly has a lot of experience with Bausch and their products.
5. In 2011 they acquired PharmaSwiss.
6. Over the last 20 yrs they have mostly grown to a behemoth by acquiring up and coming small caps and using their worldwide operations to increase sales of these drugs/products.
All in all, none of these facts seem important alone, but seeing a lot of coincidences and things popping up, has me keeping my eye on them for any more clues. I don't have to tell you how lucrative it could be, to figure out the merger partner before the merger, could be. Maybe more lucrative than RLFTF, since by my calculations, NeuroRX stands to bring in more than Relief due to their pipeline and 50/50 split of the most profitable pharma market (the US currently comprises 47% of the worldwide drug market), and their suicide prevention drug will most likely sell billions too. Yes, that's correct, 47%. Here in the US, we love our drugs.
For now, as I'm patiently waiting for RLFTF to explode, I'm also looking ahead to new opportunities for the future. I'm watching closely and will look for more clues, specifically common execs on other BOD's, current execs that worked at the same previous companies, etc. I know Javitt has a long resume working for/with a lot of BP's and connections with certain BP's that are likely candidates as well, but for now BHC is on my short list.
Well I guess you were proven wrong. It wasn't a flat out lie. It most definitely did say that this morning. You're obviously still upset at CYDY tanking.
What the? 0 logic in that. Hold for months and then dump on the night before?
What a great post to summarize how we feel about this.
So Samiair is air, as in lungs? Either IV or inhaler? And the Samivir is viral? I know I can't be the only one that assumed air was for inhaler and vir was for the IV. Apparently many others on Ywho are still struggling. Lol. And there is another trademark for Samivip. Lolol
That still confuses me. On the one hand Javitt using Samiair for the IV version in speech and slides should be enough, but my logic center is still asking what samivir is then?
And to further complicate, samivir is at the top of the edison popup, but samiair is under it.
Samiair is not the inhaled version. It simply is Aviptadil.
I always thought the IV form of Aviptadil was Samivir too and the inhaled version was Samiair, but Javitt has referred to the IV form of Aviptadil as Samiair. Look at the Solebury Trout video, 1:32 mark and slide at 16:57 mark. He uses the term Samiair as the IV version of Aviptadil.
Great point
When you think about this Strunk and White comment in the job listing, regarding PR's and the lack of, it all makes perfect sense.
Strunk and White summarized:
Vigorous writing is concise. A sentence should contain no unnecessary words, a paragraph no unnecessary sentences, for the same reason that a drawing should have no unnecessary lines and a machine no unnecessary parts. This requires not that the writer make all his sentences short, or that he avoid all detail and treat his subjects only in outline, but that he make every word tell.
—?"Elementary Principles of Composition", The Elements of Style[12]
He definitely has a good sense of humor.
Agree. So many nuggets to dig up.
Anyone want to be Javitt's asst? My plate is full, or I would.
Chief of Staff and Assistant to the CEO
NeuroRx, Inc.
Greater Philadelphia AreaPosted 1 day ago
SAVEEASY APPLY
Job description
Reports to the CEO of a rapidly growing biopharma company that is preparing for public market entry. Must be an MBA graduate from top -10 US/UK business school with GPA of 3.9 or higher.
Life sciences/biotechnology undergraduate strongly preferred.
Organizes all corporate communications and internal meetings. Identifies and remediates sources of failure before they fail.
Manages external communications. Develops top-level corporate strategy. Interface with investors and stock exchange. Makes the trains run on time and delivers the mail. Highly organized. Uniquely literate.
Impeccable OED-focused writing skills are essential to success. Has best friends named Strunk and White and consults with them daily. Provides people glue at all times. Thrives on chaos.
Empowers the CEO to present the best possible face internally and externally.
Able to write the rule book. It helps to be able to leap tall buildings in a single bound.
Our corporate motto is: The day is short, the work is enormous, the workers are inadequate, the reward is extraordinary, and the master of the house is insistent.
Salary and Equity package in excess of $250k.
https://www.linkedin.com/mwlite/jobs/view/2206996481?referenceId=pNoY%2F3k7QrCydPMxAe%2BDgw%3D%3D&eBP=JOB_SEARCH_ORGANIC
Beyond COVID-19, Relief’s objective is to establish RLF-100™ as the standard of care for Intensive Care Units (ICUs) in acute as well as chronic contexts to prevent and cure respiratory failure and its complications.
RLF-100 BEYOND COVID-19
Standard of Care in ICU to prevent / cure respiratory failure
https://relieftherapeutics.com/pipeline/
Relax. We are good.
"A randomized placebo-controlled trial of Aviptadil is underway that has enrolled more than 130 patients. In that trial, no drug-related serious adverse effects were seen and an independent data safety board determined that the trial should continue with a clear possibility that a difference between RLF-100 and placebo will be seen."
https://clinicaltrials.gov/ProvidedDocs/39/NCT04453839/ICF_002.pdf
I would hope they have lots more of staff, since they have 100 apps on file for every treatment and device etc., but I agree. Can't hurt to have Rem outta the way.
My read was a full approval for adults and a EUA for kids.
A great point in a perfect world, but they have hundreds of millions reasons why they have influence at the FDA and in this administration, but hopefully the science will prevail eventually.
He didn't call the other side names, while you call them everything in most of your posts. Why can't you see? Your TDS is making you crazy.